The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimer’s disease in vitro and in vivo

M. Leiros, E. Alonso, M. E. Rateb, R. Ebel, M. Jaspars, A. Alfonso, L. M. Botana*

*Corresponding author for this work

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Anhydroexfoliamycin (1) and undecylprodigiosin (2) have been previously described as neuroprotective molecules against oxidative stress in neurons. Since oxidative stress is strongly correlated with neurodegenerative diseases, we have evaluated their effects over the principal hallmarks of Alzheimer's disease (AD). Both compounds were tested in vitro in two different neuroblastoma cellular models, one for amyloid precursor protein metabolism studies (BE(2)-M17) and another one specific for taupathology in AD (SH-SY5Y-TMHT441). Amyloid-beta (A beta) levels, beta-secretase (BACE1) activity, tau phosphorylation, extracellular signal-regulated kinase (ERK) and glycogen synthase kinase-3beta (GSK3 beta) expression were analyzed and while undecylprodigiosin (2) produced poor results, anhydroexfoliamycin (1) strongly inhibited GSK3 beta, reducing tau phosphorylation in vitro (0.1 mu M). A competitive assay of anhydroexfoliamycin (1) and the specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, showed that the reduction of the phosphorylated tau levels is mediated by the JNK pathway in SH-SY5Y-TMHT441 cells. Thus, this compound was tested in vivo by intraperitoneal administration in 3xTg-AD mice, confirming the positive results registered in the in vitro assays. This work presents anhydroexfoliamycin (1) as a promising candidate for further studies in drug development against neurodegenerative diseases. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)26-35
Number of pages10
JournalNeuroscience
Volume305
Early online date3 Aug 2015
DOIs
Publication statusPublished - 1 Oct 2015

Keywords

  • N-TERMINAL KINASE
  • TAU-PROTEIN
  • SYNAPTIC DYSFUNCTION
  • HYPOTHESIS
  • THERAPY
  • MODEL
  • BETA
  • THERAPEUTICS
  • PATHWAYS

Cite this